Kyverna Therapeutics (NASDAQ:KYTX) just reported results for the first quarter of 2024.
- Kyverna Therapeutics reported earnings per share of -$1.12. This was below the analyst estimate for EPS of -84 cents.
- The company did not report any revenue for the quarter.